Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ALXN1840 Enteric-Coated Tablets in Healthy Adults
NCT05303324Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Oct 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atn-224 in Wilson disease (WD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Total Molybdenum and Area Under The Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration of Total Molybdenum. Started Jul 2019; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT05303324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303324.